Memorial Sloan Kettering Cancer Center, New York, NY
Carol Aghajanian , Robert L. Coleman , Amit M. Oza , Domenica Lorusso , Ana Oaknin , Andrew Peter Dean , Nicoletta Colombo , Johanne I Weberpals , Andrew R. Clamp , Giovanni Scambia , Alexandra Leary , Robert W. Holloway , Peter C.C. Fong , Jeffrey C. Goh , David M. O'Malley , Susana N. Banerjee , Kenton Wride , Teresa Cameron , Jonathan A. Ledermann
Background: In ARIEL3, pts were randomized 2:1 (oral rucaparib 600 mg or placebo). Rucaparib significantly improved progression-free survival (PFS) vs placebo in all primary analysis groups (Coleman et al. Lancet. 2017;390:1949-61). An exploratory subgroup analysis of ARIEL3 pts with or without bulky residual disease ( > 2 cm per blinded independent central review [BICR]) at baseline is reported. Methods: Pts were assigned to 2 analysis subgroups: with or without bulky residual disease at baseline. PFS was assessed in 3 predefined cohorts: BRCA mutant; homologous recombination deficient (HRD) (BRCA mutant or BRCA wild type/high loss of heterozygosity); and intent-to-treat (ITT) population. Results: PFS data for each subgroup (visit cutoff date 15 Apr 2017) by status of bulky disease at baseline are summarized in the Table. Safety data were consistent with data reported previously. In the rucaparib arm, the most common grade ≥3 treatment-emergent adverse event in pts with and pts without bulky disease was anemia (20.0% and 18.5%, respectively). Clinical trial information: NCT01968213 Conclusions: Rucaparib improved PFS vs placebo in all 3 predefined cohorts for both pts with and without bulky residual disease. PFS benefit with rucaparib was largest in pts with BRCA-mutant rOC.
Cohort | Rucaparib, n | Placebo, n | PFS (investigator review) | PFS (BICR) | ||
---|---|---|---|---|---|---|
HR (95% CI) | Median PFS, mo; P value* | HR (95% CI) | Median PFS, mo; Pvalue* | |||
Rucaparib vs placebo | Rucaparib vs placebo | |||||
Bulky disease at baseline (per BICR) | ||||||
Yes | ||||||
BRCA mutant | 21 | 10 | 0.09 (0.02–0.37) | 11.1 vs 2.8; P= 0.0002 | 0.13 (0.03–0.55) | 17.1 vs 2.9; P= 0.0028 |
HRD | 39 | 18 | 0.30 (0.13–0.69) | 8.3 vs 2.8; P= 0.0030 | 0.58 (0.25–1.34) | 8.3 vs 2.9; P= 0.1994 |
ITT | 71 | 29 | 0.40 (0.24–0.69) | 8.2 vs 2.9; P= 0.0007 | 0.46 (0.26–0.81) | 8.3 vs 3.0; P= 0.0057 |
No | ||||||
BRCA mutant | 109 | 56 | 0.26 (0.17–0.40) | 16.6 vs 5.6; P< 0.0001 | 0.22 (0.13–0.37) | 26.8 vs 5.5; P< 0.0001 |
HRD | 197 | 100 | 0.31 (0.23–0.43) | 13.8 vs 5.5; P< 0.0001 | 0.32 (0.22–0.47) | 24.7 vs 5.6; P< 0.0001 |
ITT | 304 | 160 | 0.36 (0.29–0.46) | 11.0 vs 5.4; P< 0.0001 | 0.34 (0.26–0.45) | 16.2 vs 5.4; P< 0.0001 |
*Stratified log-rank P value.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2019 ASCO Annual Meeting
First Author: Robert L. Coleman
2023 ASCO Annual Meeting
First Author: Sumitra Ananda
2022 ASCO Annual Meeting
First Author: Robert L. Coleman
2023 ASCO Annual Meeting
First Author: Bradley Corr